Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Merck
Colorcon
Farmers Insurance
Teva
Citi
Dow
US Army
Chubb

Generated: January 17, 2018

DrugPatentWatch Database Preview

Salmeterol xinafoate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for salmeterol xinafoate and what is the scope of salmeterol xinafoate freedom to operate?

Salmeterol xinafoate
is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in two NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Salmeterol xinafoate has seventy-eight patent family members in forty-one countries.

There are eighteen drug master file entries for salmeterol xinafoate. Two suppliers are listed for this compound.
Pharmacology for salmeterol xinafoate
Medical Subject Heading (MeSH) Categories for salmeterol xinafoate

US Patents and Regulatory Information for salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for salmeterol xinafoate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for salmeterol xinafoate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,032,666 Inhalation device ➤ Subscribe
2,006,107,948 ➤ Subscribe
6,792,945 Inhalation device ➤ Subscribe
2,007,107,724 ➤ Subscribe
6,378,519 Inhalation device ➤ Subscribe
5,860,419 Inhalation device ➤ Subscribe
5,590,645 Inhalation device ➤ Subscribe
7,389,775 Inhalation device ➤ Subscribe
6,536,427 Inhalation device ➤ Subscribe
7,225,808 Inhalation device ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for salmeterol xinafoate

Supplementary Protection Certificates for salmeterol xinafoate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90012 Netherlands ➤ Subscribe PRODUCT NAME: SALMETEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN FLUTICASONPROPIONAAT,IN HET BIJZONDER SALMETEROLXINAFOAAT EN FLUTICASONPROPIONAAT; NATL REGISTRATION NO/DATE: RVG 23529 - RVG 23534 19990112; FIRST REGISTRATION: SE 14591 - 14596 19980907
/1999 Austria ➤ Subscribe PRODUCT NAME: SALMETEROL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH DES 1-HYDROXY-2-NAPHTHOATS (XINAFOAT) UND FLUTICASON PROPIONAT; NAT. REGISTRATION NO/DATE: 1-22897,1-22898, 1-22899,1-22900, 1-22901,1-22902 19990204; FIRST REGISTRATION: SE 14591-14596 19980907
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
US Army
Merck
Argus Health
Dow
US Department of Justice
QuintilesIMS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot